Effects of docetaxel and TH1902 on AN3-CA endometrial cancer xenografts. Comparative efficacy of docetaxel and TH1902 on endometrial cancer xenografts tumor growth. Immunodeficient mice bearing subcutaneous AN3-CA tumors were intravenously injected weekly with either vehicle, docetaxel (at its MTD and quarter MTD doses; 15 and 3.75 mg/kg, respectively), or TH1902 (at a dosage which contains a quantity of bound docetaxel equal to the docetaxel doses; 35 and 8.75 mg/kg, respectively). Low dose docetaxel group was euthanized at vehicle group endpoint (Day 14) whereas TH1902 low dose, docetaxel and TH1902 high doses were monitored for a prolonged period (Days 21, 29 and 54 post start of treatments, respectively) as described in the methods section. Colored dots below the abscissa indicate drug treatments for all groups, high doses of docetaxel and TH1902 were cut by half (7.5 and 17.5 mg/kg, respectively) for the third and fourth treatments because of docetaxel group weight loss (small dots). Data are represented as mean ± SEM (n = 6 mice/group).